ASP Isotopes Inc. Announces Pricing of $60 Million Underwritten Registered Direct Offering of Common Stock
ASP Isotopes (NASDAQ:ASPI) has announced the pricing of an underwritten registered direct offering of 7.5 million shares of common stock at $8.00 per share to a single fundamental institutional investor. The offering is expected to generate gross proceeds of approximately $60 million.
The offering, expected to close around July 25, 2025, will be managed jointly by Cantor and Canaccord Genuity as book-running managers, with Ocean Wall Limited acting as financial advisor. The company plans to use the net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures.
ASP Isotopes (NASDAQ:ASPI) ha annunciato il prezzo di un'offerta diretta registrata sottoscritta di 7,5 milioni di azioni ordinarie a 8,00 dollari per azione a un unico investitore istituzionale fondamentale. L'offerta dovrebbe generare proventi lordi di circa 60 milioni di dollari.
L'offerta, che si prevede si concluda intorno al 25 luglio 2025, sarà gestita congiuntamente da Cantor e Canaccord Genuity come lead manager, con Ocean Wall Limited che agirà come consulente finanziario. La società intende utilizzare i proventi netti per scopi aziendali generali, inclusi capitale circolante, spese operative e investimenti in capitale.
ASP Isotopes (NASDAQ:ASPI) ha anunciado el precio de una oferta directa registrada suscrita de 7.5 millones de acciones comunes a $8.00 por acción a un único inversor institucional fundamental. Se espera que la oferta genere ingresos brutos de aproximadamente $60 millones.
La oferta, que se espera cierre alrededor del 25 de julio de 2025, será gestionada conjuntamente por Cantor y Canaccord Genuity como administradores principales del libro, con Ocean Wall Limited actuando como asesor financiero. La empresa planea usar los ingresos netos para fines corporativos generales, incluyendo capital de trabajo, gastos operativos y gastos de capital.
ASP Isotopes (NASDAQ:ASPI)는 단일 주요 기관 투자자에게 보통주 750만 주를 주당 8.00달러에 인수 확정 등록 직접 공모의 가격을 발표했습니다. 이번 공모를 통해 약 6,000만 달러의 총 수익이 예상됩니다.
본 공모는 2025년 7월 25일경 마감될 예정이며, Cantor와 Canaccord Genuity가 공동으로 주관사를 맡고 Ocean Wall Limited가 재무 자문 역할을 합니다. 회사는 순수익을 일반 기업 목적, 즉 운전자본, 운영비용 및 자본 지출에 사용할 계획입니다.
ASP Isotopes (NASDAQ:ASPI) a annoncé le prix d'une offre directe enregistrée souscrite de 7,5 millions d'actions ordinaires à 8,00 $ par action à un seul investisseur institutionnel fondamental. L'offre devrait générer des recettes brutes d'environ 60 millions de dollars.
L'offre, qui devrait se clôturer vers le 25 juillet 2025, sera gérée conjointement par Cantor et Canaccord Genuity en tant que chefs de file, avec Ocean Wall Limited agissant en tant que conseiller financier. La société prévoit d'utiliser le produit net à des fins générales d'entreprise, notamment pour le fonds de roulement, les dépenses d'exploitation et les dépenses en capital.
ASP Isotopes (NASDAQ:ASPI) hat die Preisfestsetzung eines gezeichneten, registrierten Direktangebots von 7,5 Millionen Stammaktien zu 8,00 USD pro Aktie an einen einzelnen institutionellen Großinvestor bekanntgegeben. Das Angebot wird voraussichtlich Bruttoerlöse von etwa 60 Millionen USD erzielen.
Das Angebot, das voraussichtlich um den 25. Juli 2025 abgeschlossen wird, wird gemeinsam von Cantor und Canaccord Genuity als Bookrunner verwaltet, wobei Ocean Wall Limited als Finanzberater fungiert. Das Unternehmen plant, die Nettoerlöse für allgemeine Unternehmenszwecke zu verwenden, einschließlich Betriebskapital, Betriebskosten und Investitionsausgaben.
- Secured significant funding of $60 million through stock offering
- Strong institutional backing with single fundamental investor participation
- Proceeds will strengthen working capital and support operational growth
- Potential dilution for existing shareholders with 7.5 million new shares
- Share offering price may put downward pressure on stock price
Insights
ASP Isotopes raising $60M through stock offering at $8/share strengthens balance sheet but dilutes existing shareholders by ~7.5M shares.
ASP Isotopes has secured a
The pricing represents a targeted placement to a fundamental institutional investor, suggesting strong conviction in ASP's business model from a sophisticated market participant. The involvement of two prominent investment banks (Cantor and Canaccord Genuity) as joint book-running managers adds credibility to the offering.
While the company will benefit from the capital influx, existing shareholders face dilution from the 7.5 million new shares being issued. The company plans to allocate proceeds toward general corporate purposes, including working capital, operating expenses, and capital expenditures – indicating potential for accelerated operational expansion rather than debt reduction.
The offering's structure as a registered direct offering provides regulatory transparency while still targeting a specific investor, offering a balance between efficiency and compliance. The expected closing date of July 25th suggests minimal execution risk. The company utilized the shelf registration mechanism (S-3 form), demonstrating forward planning in its capital raising strategy.
WASHINGTON, July 23, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), today announced the pricing of an underwritten registered direct offering of 7,500,000 shares of its common stock at a price of
Cantor and Canaccord Genuity acted as joint book-running managers for the offering. Ocean Wall Limited acted as financial advisor.
The net proceeds of this offering are expected to be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.
The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”) and a related registration statement that was filed with the SEC pursuant to Rule 462(b) under the Securities Act of 1933 (and became automatically effective upon filing). This offering is being made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and accompanying prospectus relating to these securities may also be obtained by sending a request to: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com; or Canaccord Genuity LLC, Attention: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).
There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as “believes,” “plans,” “anticipates,” “expects,” “estimates,” “projects,” “will,” “may,” “might,” and words of a similar nature. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including: risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering; the intended use of net proceeds from the public offering; the impact of general economic, industry or political conditions in the United States or internationally; the failure to obtain necessary regulatory approvals and third party consents for the proposed acquisition of Renergen; disruption from the proposed acquisition of Renergen making it more difficult to maintain business and operational relationships; significant transaction costs and unknown liabilities related to the proposed acquisition of Renergen; litigation or regulatory actions related to the proposed acquisition of Renergen; the outcomes of various strategies and projects undertaken by the Company; the potential impact of laws or government regulations or policies in South Africa, the United Kingdom or elsewhere; our reliance on the efforts of third parties; our ability to complete the proposed the construction and commissioning of our enrichment plant(s) or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part I, Item 1A. “Risk Factors” of the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and any amendments thereto and in the company’s subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
FAQ
How much money is ASP Isotopes (ASPI) raising in its July 2025 stock offering?
What is the price per share for ASPI's July 2025 stock offering?
How will ASP Isotopes use the proceeds from its $60M stock offering?
Who are the underwriters for ASPI's July 2025 stock offering?
When will ASPI's $60M stock offering close?
